Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

General Counsel/Secretary

President and CEO

SVP,Clinical & Medical Affairs

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative d...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-11	Premium	acquired	Premium	Premium	Premium	General Counsel/Secretary
2024-02-11	Premium	sold (taxes)	Premium	Premium	Premium	General Counsel/Secretary
2024-02-11	Premium	sold (taxes)	Premium	Premium	Premium	President and CEO
2024-02-11	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-02-08	Premium	bought	Premium	Premium	Premium	-
2024-02-06	Premium	bought	Premium	Premium	Premium	-
2024-02-06	Premium	bought	Premium	Premium	Premium	-
2023-12-29	Premium	bought	Premium	Premium	Premium	-
2023-02-11	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-02-11	Premium	sold (taxes)	Premium	Premium	Premium	General Counsel/Secretary
2023-02-11	Premium	sold (taxes)	Premium	Premium	Premium	SVP,Clinical & Medical Affairs
2023-02-11	Premium	acquired	Premium	Premium	Premium	General Counsel/Secretary
2023-02-11	Premium	sold (taxes)	Premium	Premium	Premium	President and CEO
2023-02-11	Premium	acquired	Premium	Premium	Premium	SVP,Clinical & Medical Affairs
2022-12-01	Premium	gifted	Premium	Premium	Premium	-
2022-06-30	Premium	sold (taxes)	Premium	Premium	Premium	President and CEO
2022-06-30	Premium	acquired	Premium	Premium	Premium	President and CEO
2022-03-31	Premium	bought	Premium	Premium	Premium	President and CEO
2022-03-31	Premium	acquired	Premium	Premium	Premium	President and CEO
2022-03-31	Premium	sold (taxes)	Premium	Premium	Premium	President and CEO
2022-03-28	Premium	bought	Premium	Premium	Premium	-
2022-03-25	Premium	bought	Premium	Premium	Premium	-
2022-03-25	Premium	bought	Premium	Premium	Premium	President and CEO
2022-03-25	Premium	bought	Premium	Premium	Premium	-
2022-03-24	Premium	bought	Premium	Premium	Premium	-

LCTX - Lineage Cell Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for LCTX